A small phase 2a trial of GH001, an investigational psychedelic compound, found a rapid reduction in postpartum depression symptoms. Larger studies are needed to assess safety and durability.
New prospective data on 56 first-trimester vortioxetine exposures found no major malformations, offering reassuring but still preliminary reproductive safety information.
Vigilance is required in screening women who present with postpartum depression; a subset of women who screen positive for depression may actually have bipolar disorder.
This study provides reassuring data on the use of mirtazapine during pregnancy, demonstrating no association between exposure and risk of major malformations or pregnancy loss.
About 60% of women with mood disorders experience premenstrual exacerbation or PME of their mood during the premenstrual phase of their cycle.
The Women's Mental Health Program at the University of Arkansas for Medical Sciences has observed a fourfold increase in postpartum psychosis in the pandemic.
About 15% of women will experience postpartum depression after the birth of a child. While most of those women will have unipolar depression, a certain number of women will have bipolar depression. At this juncture, [...]
St. John’s wort (Hypericum perforatum) is an herbal preparation which has been shown, in some studies, to be effective for the treatment of mild to moderate depressive symptoms. St. John’s wort is now one [...]
Women are at increased risk for depressive symptoms during the menopause transition. It has long been suspected that falling estrogen levels play a role in triggering the onset of depression; however, if all women experience [...]
Transcranial magnetic stimulation or TMS is similar to ECT but uses electromagnetic pulses to generate electrical current in specific regions of the brain that are known to modulate mood. Â TMS is less likely to cause [...]
